ロード中...
Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common type of cancers worldwide. However, current therapeutic approaches for this epidemic disease are limited, and its 5-year survival rate hasn't been improved in the past decades. Patient-derived xenograft (PDX) tumor models have become an ex...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2015
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4868698/ https://ncbi.nlm.nih.gov/pubmed/26701727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6684 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|